Activated protein C: A promising drug with multiple effects?

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 5, 2009, Pages 620-626

  Loubele, Sarah T B G ^a   Spronk, H M H ^a   ten Cate, H ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Animal injury models; Anti coagulation; APC; Cytoprotection

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; DROTRECOGIN; ENDOTHELIAL PROTEIN C RECEPTOR; PROTEIN BAX; PROTEIN P53; PROTEINASE ACTIVATED RECEPTOR 1; PROTEIN C;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CELL FUNCTION; CELL PROTECTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTINUOUS INFUSION; DIABETIC NEPHROPATHY; DISEASE SEVERITY; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; ENDOTHELIUM CELL; ENDOTOXEMIA; GENE EXPRESSION REGULATION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; IN VITRO STUDY; INFLAMMATION; LUNG INJURY; MORTALITY; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; REPERFUSION INJURY; RISK ASSESSMENT; RISK REDUCTION; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION; STEADY STATE; THROMBOSIS; ANIMAL; CELL; DRUG EFFECT; ENZYME ACTIVATION; METABOLISM; REVIEW;

ANIMALS; ANTICOAGULANTS; CELLS; CYTOPROTECTION; ENZYME ACTIVATION; HUMANS; PROTEIN C; SIGNAL TRANSDUCTION;

EID: 67649890872     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709788167547     Document Type: Article

References (77)

1. Mackman, N.; Tilley, R.E.; Key, N.S. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler. Thromb. Vasc. Biol., 2007, 27, 1687-93.
2. Girard, T.J.; Warren, L.A.; Novotny, W.F.; Likert, K.M.; Brown, S.G.; Miletich, J.P.; Broze, G.J., Jr. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature, 1989, 338, 518-20.
3. Baugh, R.J.; Broze, G.J., Jr.; Krishnaswamy, S. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J. Biol. Chem., 1998, 273, 4378-86.
4. Spronk, H.M.; Govers-Riemslag, J.W.; ten Cate, H. The blood coagulation system as a molecular machine. Bioassays, 2003, 25, 1220-8.
5. Beresford, C.H. Antithrombin III deficiency. Blood Rev., 1988, 2, 239-50.
6. Zhang, L.; Jhingan, A.; Castellino, F.J. Role of individual gammacarboxyglutamic acid residues of activated human protein C in defining its in vitro anticoagulant activity. Blood, 1992, 80, 942-52.
7. Liaw, P.C.; Mather, T.; Oganesyan, N.; Ferrell, G.L.; Esmon, C.T. Identification of the protein C/activated protein C binding sites on the endothelial cell protein C receptor. Implications for a novel mode of ligand recognition by a major histocompatibility complex class 1-type receptor. J. Biol. Chem., 2001, 276, 8364-70.
8. Taylor, F.B., Jr.; Peer, G.T.; Lockhart, M.S.; Ferrell, G.; Esmon, C.T. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood, 2001, 97, 1685-8.
9. Stearns-Kurosawa, D.J.; Kurosawa, S.; Mollica, J.S.; Ferrell, G.L.; Esmon, C.T. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc. Natl. Acad. Sci. USA, 1996, 93, 10212-6.
10. Esmon, C.T. Coagulation and inflammation. J. Endotoxin. Res., 2003, 9, 192-8.
11. Regan, L.M.; Stearns-Kurosawa, D.J.; Kurosawa, S.; Mollica, J.; Fukudome, K.; Esmon, C.T. The endothelial cell protein C receptor. Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors. J. Biol. Chem., 1996, 271, 17499-503.
12. Rezaie, A.R.; Cooper, S.T.; Church, F.C.; Esmon, C.T. Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. J. Biol. Chem., 1995, 270, 25336-9.
13. Odet, F.; Guyot, R.; Leduque, P.; Le Magueresse-Battistoni, B. Evidence for similar expression of protein C inhibitor and the urokinase-type plasminogen activator system during mouse testis development. Endocrinology, 2004, 145, 1481-9.
14. Okajima, K.; Koga, S.; Kaji, M.; Inoue, M.; Nakagaki, T.; Funatsu, A.; Okabe, H.; Takatsuki, K.; Aoki, N. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects. Thromb. Haemost., 1990, 63, 48-53.
15. Berger, H., Jr.; Kirstein, C.G.; Orthner, C.L. Pharmacokinetics of activated protein C in guinea pigs. Blood, 1991, 77, 2174-84.
16. Dreyfus, M.; Magny, J.F.; Bridey, F.; Schwarz, H.P.; Planche, C.; Dehan, M.; Tchernia, G. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N. Engl. J. Med., 1991, 325, 1565-8.
17. Griffin, J.H.; Evatt, B.; Zimmerman, T.S.; Kleiss, A.J.; Wideman, C. Deficiency of protein C in congenital thrombotic disease. J. Clin. Invest., 1981, 68, 1370-3.
18. Broekmans, A.W.; Veltkamp, J.J.; Bertina, R.M. Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N. Engl. J. Med., 1983, 309, 340-4.
19. Castoldi, E.; Rosing, J. Factor V Leiden: a disorder of factor V anticoagulant function. Curr. Opin. Hematol., 2004, 11, 176-81.
20. Greengard, J.S.; Sun, X.; Xu, X.; Fernandez, J.A.; Griffin, J.H.; Evatt, B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet, 1994, 343, 1361-2.
21. Bertina, R.M.; Koeleman, B.P.; Koster, T.; Rosendaal, F.R.; Dirven, R.J.; de Ronde, H.; van der Velden, P.A.; Reitsma, P.H. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature, 1994, 369, 64-7.
22. Ye, Z.; Liu, E.H.; Higgins, J.P.; Keavney, B.D.; Lowe, G.D.; Collins, R.; Danesh, J. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet, 2006, 367, 651-8.
23. Mahmoodi, B.K.; Brouwer, J.L.; Veeger, N.J.; van der Meer, J. Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study. Circulation, 2008, 118, 1659-67.
24. Eitzman, D.T.; Westrick, R.J.; Shen, Y.; Bodary, P.F.; Gu, S.; Manning, S.L.; Dobies, S.L.; Ginsburg, D. Homozygosity for factor V Leiden leads to enhanced thrombosis and atherosclerosis in mice. Circulation, 2005, 111, 1822-5.
25. Jalbert, L.R.; Rosen, E.D.; Moons, L.; Chan, J.C.; Carmeliet, P.; Collen, D.; Castellino, F.J. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J. Clin. Invest., 1998, 102, 1481-8.
26. Lay, A.J.; Liang, Z.; Rosen, E.D.; Castellino, F.J. Mice with a severe deficiency in protein C display prothrombotic and proinflammatory phenotypes and compromised maternal reproductive capabilities. J. Clin. Invest., 2005, 115, 1552-61.
27. Araki, H.; Nishi, K.; Ishihara, N.; Okajima, K. Inhibitory effects of activated protein C and heparin on thrombotic arterial occlusion in rat mesenteric arteries. Thromb. Res., 1991, 62, 209-16.
28. Malm, K.; Dahlback, B.; Arnljots, B. Prevention of thrombosis following deep arterial injury in rats by bovine activated protein C requiring co-administration of bovine protein S. Thromb. Haemost., 2003, 90, 227-34.
29. Coughlin, S.R. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb. Haemost., 2005, 3, 1800-14.
30. Vu, T.K.; Hung, D.T.; Wheaton, V.I.; Coughlin, S.R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell, 1991, 64, 1057-68.
31. Riewald, M.; Petrovan, R.J.; Donner, A.; Ruf, W. Activated protein C signals through the thrombin receptor PAR1 in endothelial cells. J. Endotoxin. Res., 2003, 9, 317-21.
32. Bae, J.S.; Yang, L.; Rezaie, A.R. Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cells. Proc. Natl. Acad. Sci. USA, 2007, 104, 2867-72.
33. Bae, J.S.; Yang, L.; Rezaie, A.R. Lipid raft localization regulates the cleavage specificity of protease activated receptor 1 in endothelial cells. J. Thromb. Haemost., 2008, 6, 954-61.
34. Yang, X.V.; Banerjee, Y.; Fernandez, J.A.; Deguchi, H.; Xu, X.; Mosnier, L.O.; Urbanus, R.T.; de Groot, P.G.; White-Adams, T.C.; McCarty, O.J.; Griffin, J.H. Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. Proc. Natl. Acad. Sci. USA, 2009, 106, 274-9.
35. White, T.C.; Berny, M.A.; Tucker, E.I.; Urbanus, R.T.; de Groot, P.G.; Fernandez, J.A.; Griffin, J.H.; Gruber, A.; McCarty, O.J. Protein C supports platelet binding and activation under flow: role of glycoprotein Ib and apolipoprotein E receptor 2. J. Thromb. Haemost., 2008, 6, 995-1002.
36. Joyce, D.E.; Gelbert, L.; Ciaccia, A.; DeHoff, B.; Grinnell, B.W. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J. Biol. Chem., 2001, 276, 11199-203.
37. Cheng, T.; Liu, D.; Griffin, J.H.; Fernandez, J.A.; Castellino, F.; Rosen, E.D.; Fukudome, K.; Zlokovic, B.V. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat. Med., 2003, 9, 338-42.
38. Riewald, M.; Petrovan, R.J.; Donner, A.; Mueller, B.M.; Ruf, W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science, 2002, 296, 1880-2.
39. Joyce, D.E.; Grinnell, B.W. Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit. Care. Med., 2002, 30, S288-93.
40. Franscini, N.; Bachli, E.B.; Blau, N.; Leikauf, M.S.; Schaffner, A.; Schoedon, G. Gene expression profiling of inflamed human endothelial cells and influence of activated protein C. Circulation, 2004, 110, 2903-9.
41. Dillon, J.P.; Laing, A.J.; Cahill, R.A.; O'Brien, G.C.; Street, J.T.; Wang, J.H.; Mc Guinness, A.; Redmond, H.P. Activated protein C attenuates acute ischaemia reperfusion injury in skeletal muscle. J. Orthop. Res., 2005, 23, 1454-9.
42. Mosnier, L.O.; Zlokovic, B.V.; Griffin, J.H. The cytoprotective protein C pathway. Blood, 2007, 109, 3161-72.
43. Stephenson, D.A.; Toltl, L.J.; Beaudin, S.; Liaw, P.C. Modulation of monocyte function by activated protein C, a natural anticoagulant. J. Immunol., 2006, 177, 2115-22.
44. Kurosawa, S.; Esmon, C.T.; Stearns-Kurosawa, D.J. The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18. J. Immunol., 2000, 165, 4697-703.
45. Mosnier, L.O.; Griffin, J.H. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem. J., 2003, 373, 65-70.
46. Jian, M.Y.; Koizumi, T.; Tsushima, K.; Fujimoto, K.; Kubo, K. Activated protein C attenuates acid-aspiration lung injury in rats. Pulm. Pharmacol. Ther., 2005, 18, 291-6.
47. Wong, S.S.; Sun, N.N.; Hyde, J.D.; Ruiz, L.; Meigs, E.; Herrin, B.R.; Fastje, C.D.; Macdonald, S.J.; Witten, M.L. Drotrecogin alfa (activated) prevents smoke-induced increases in pulmonary microvascular permeability and proinflammatory cytokine IL-1beta in rats. Lung, 2004, 182, 319-30.
48. Slofstra, S.H.; Groot, A.P.; Maris, N.A.; Reitsma, P.H.; Cate, H.T.; Spek, C.A. Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment. Br. J. Pharmacol., 2006, 149, 740-6.
49. Shibata, M.; Kumar, S.R.; Amar, A.; Fernandez, J.A.; Hofman, F.; Griffin, J.H.; Zlokovic, B.V. Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation, 2001, 103, 1799-805.
50. Zlokovic, B.V.; Zhang, C.; Liu, D.; Fernandez, J.; Griffin, J.H.; Chopp, M. Functional recovery after embolic stroke in rodents by activated protein C. Ann. Neurol., 2005, 58, 474-7.
51. Mizutani, A.; Okajima, K.; Uchiba, M.; Noguchi, T. Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood, 2000, 95, 3781-7.
52. Hirose, K.; Okajima, K.; Taoka, Y.; Uchiba, M.; Tagami, H.; Nakano, K.; Utoh, J.; Okabe, H.; Kitamura, N. Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation. Ann. Surg., 2000, 232, 272-80.
53. Han, M.H.; Hwang, S.I.; Roy, D.B.; Lundgren, D.H.; Price, J.V.; Ousman, S.S.; Fernald, G.H.; Gerlitz, B.; Robinson, W.H.; Baranzini, S.E.; Grinnell, B.W.; Raine, C.S.; Sobel, R.A.; Han, D.K.; Steinman, L. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature, 2008, 451, 1076-81.
54. Isermann, B.; Vinnikov, I.A.; Madhusudhan, T.; Herzog, S.; Kashif, M.; Blautzik, J.; Corat, M.A.; Zeier, M.; Blessing, E.; Oh, J.; Gerlitz, B.; Berg, D.T.; Grinnell, B.W.; Chavakis, T.; Esmon, C.T.; Weiler, H.; Bierhaus, A.; Nawroth, P.P. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat. Med., 2007, 13, 1349-58.
55. Brownlee, M. Preventing kidney cell suicide. Nat. Med., 2007, 13, 1284-5.
56. Feistritzer, C.; Riewald, M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood, 2005, 105, 3178-84.
57. McVerry, B.J.; Garcia, J.G. Endothelial cell barrier regulation by sphingosine 1-phosphate. J. Cell. Biochem., 2004, 92, 1075-85.
58. Finigan, J.H.; Dudek, S.M.; Singleton, P.A.; Chiang, E.T.; Jacobson, J.R.; Camp, S.M.; Ye, S.Q.; Garcia, J.G. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J. Biol. Chem., 2005, 280, 17286-93.
59. Bae, J.S.; Yang, L.; Manithody, C.; Rezaie, A.R. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood, 2007, 110, 3909-16.
60. Liu, D.; Cheng, T.; Guo, H.; Fernandez, J.A.; Griffin, J.H.; Song, X.; Zlokovic, B.V. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat. Med., 2004, 10, 1379-83.
61. Cheng, T.; Petraglia, A.L.; Li, Z.; Thiyagarajan, M.; Zhong, Z.; Wu, Z.; Liu, D.; Maggirwar, S.B.; Deane, R.; Fernandez, J.A.; La-Rue, B.; Griffin, J.H.; Chopp, M.; Zlokovic, B.V. Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat. Med., 2006, 12, 1278-85.
62. Taylor, F.B., Jr.; Chang, A.; Esmon, C.T.; D'Angelo, A.; Vigano-D'Angelo, S.; Blick, K.E. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J. Clin. Invest., 1987, 79, 918-25.
63. Favory, R.; Lancel, S.; Marechal, X.; Tissier, S.; Neviere, R. Cardiovascular protective role for activated protein C during endotoxemia in rats. Intensive Care. Med., 2006, 32, 899-905.
64. Iba, T.; Kidokoro, A.; Fukunaga, M.; Nagakari, K.; Shirahama, A.; Ida, Y. Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model. Crit. Care. Med., 2005, 33, 368-72.
65. Sharma, G.R.; Gerlitz, B.; Berg, D.T.; Cramer, M.S.; Jakubowski, J.A.; Galbreath, E.J.; Heuer, J.G.; Grinnell, B.W. Activated protein C modulates chemokine response and tissue injury in experimental sepsis. Adv. Exp. Med. Biol., 2008, 614, 83-91.
66. Esmon, C.T. Is APC activation of endothelial cell PAR1 important in severe sepsis?: No. J. Thromb. Haemost., 2005, 3, 1910-1.
67. Ruf, W. Is APC activation of endothelial cell PAR1 important in severe sepsis?: Yes. J. Thromb. Haemost., 2005, 3, 1912-4.
68. Slofstra, S.H.; ten Cate, H.; Spek, C.A. Signal transduction induced by activated protein C: no role in protection against sepsis? Trends Mol. Med., 2006, 12, 374-81.
69. Pawlinski, R.; Pedersen, B.; Schabbauer, G.; Tencati, M.; Holscher, T.; Boisvert, W.; Andrade-Gordon, P.; Frank, R.D.; Mackman, N. Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood, 2004, 103, 1342-7.
70. Levi, M.; Dorffler-Melly, J.; Reitsma, P.; Buller, H.; Florquin, S.; van der Poll, T.; Carmeliet, P. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood, 2003, 101, 4823-7.
71. Kerschen, E.J.; Fernandez, J.A.; Cooley, B.C.; Yang, X.V.; Sood, R.; Mosnier, L.O.; Castellino, F.J.; Mackman, N.; Griffin, J.H.; Weiler, H. Endotoxemia and sepsis mortality reduction by nonanticoagulant activated protein C. J. Exp. Med., 2007, 204, 2439-48.
72. Mesters, R.M.; Helterbrand, J.; Utterback, B.G.; Yan, B.; Chao, Y.B.; Fernandez, J.A.; Griffin, J.H.; Hartman, D.L. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit. Care. Med., 2000, 28, 2209-16.
73. Faust, S.N.; Levin, M.; Harrison, O.B.; Goldin, R.D.; Lockhart, M.S.; Kondaveeti, S.; Laszik, Z.; Esmon, C.T.; Heyderman, R.S. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N. Engl. J. Med., 2001, 345, 408-16.
74. Bernard, G.R.; Vincent, J.L.; Laterre, P.F.; LaRosa, S.P.; Dhainaut, J.F.; Lopez-Rodriguez, A.; Steingrub, J.S.; Garber, G.E.; Helterbrand, J.D.; Ely, E.W.; Fisher, C.J., Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med., 2001, 344, 699-709.
75. Polderman, K.H.; Girbes, A.R. Drug intervention trials in sepsis: divergent results. Lancet, 2004, 363, 1721-3.
76. Bernard, G.R.; Margolis, B.D.; Shanies, H.M.; Ely, E.W.; Wheeler, A.P.; Levy, H.; Wong, K.; Wright, T.J. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest, 2004, 125, 2206-16.
77. Vincent, J.L.; Bernard, G.R.; Beale, R.; Doig, C.; Putensen, C.; Dhainaut, J.F.; Artigas, A.; Fumagalli, R.; Macias, W.; Wright, T.; Wong, K.; Sundin, D.P.; Turlo, M.A.; Janes, J. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit. Care. Med., 2005, 33, 2266-77.